Innate Pharma SA (IPHA) Form 10-K Annual Reports
Innate Pharma SA (IPHA) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: IPHA
CIK: 1598599
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: I0
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PRICEWATERHOUSECOOPERS AUDIT
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerCEDRIC MAZILLE
Audit LocationLyon, France
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 6-K | 2026-09-17 | 2026-09-17 | 6-K | 0001628280-26-062360 | View SEC Doc Filr Page |
| 6-K | 2026-09-17 | 2026-06-30 | 6-K | 0001598599-26-000010 | View SEC Doc Filr Page |
| 6-K | 2026-09-17 | 2026-09-16 | 6-K | 0001628280-26-062357 | View SEC Doc Filr Page |
| 6-K | 2026-09-10 | 2026-09-10 | 6-K | 0001628280-26-061214 | View SEC Doc Filr Page |
| 6-K | 2026-09-02 | 2026-09-02 | 6-K | 0001628280-26-059963 | View SEC Doc Filr Page |
| 6-K | 2026-08-19 | 2026-08-19 | 6-K | 0001628280-26-057935 | View SEC Doc Filr Page |
| 6-K | 2026-08-14 | 2026-08-14 | 6-K | 0001628280-26-056913 | View SEC Doc Filr Page |
| 6-K | 2026-08-10 | 2026-08-10 | 6-K | 0001628280-26-054966 | View SEC Doc Filr Page |
| 6-K | 2026-07-23 | 2026-07-23 | 6-K | 0001628280-26-049273 | View SEC Doc Filr Page |
| 6-K | 2026-07-21 | 2026-07-21 | 6-K | 0001598599-26-000008 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-06-22 | — | SCHEDULE 13G/A Filing | 0000950103-26-009261 | View SEC Doc Filr Page |
| 6-K | 2026-05-22 | 2026-05-22 | 6-K | 0001628280-26-037515 | View SEC Doc Filr Page |
| 6-K | 2026-05-19 | 2026-05-19 | 6-K | 0001628280-26-036122 | View SEC Doc Filr Page |
| 6-K | 2026-05-13 | 2026-05-13 | 6-K | 0001628280-26-034383 | View SEC Doc Filr Page |
| 6-K | 2026-05-12 | 2026-05-12 | 6-K | 0001628280-26-033831 | View SEC Doc Filr Page |
| 6-K | 2026-05-06 | 2026-05-06 | 6-K | 0001628280-26-030874 | View SEC Doc Filr Page |
| 6-K | 2026-04-23 | 2026-04-23 | 6-K | 0001628280-26-026676 | View SEC Doc Filr Page |
| 6-K | 2026-04-17 | 2026-04-17 | 6-K | 0001628280-26-025688 | View SEC Doc Filr Page |
| 6-K | 2026-04-13 | 2026-04-13 | 6-K | 0001628280-26-024822 | View SEC Doc Filr Page |
| 6-K | 2026-04-13 | 2026-04-13 | 6-K | 0001628280-26-024819 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-04-10 | — | SCHEDULE 13G/A Filing | 0000950103-26-005593 | View SEC Doc Filr Page |
| 6-K | 2026-04-08 | 2026-04-08 | 6-K | 0001628280-26-024144 | View SEC Doc Filr Page |
| 6-K | 2026-04-03 | 2026-04-03 | 6-K | 0001628280-26-023471 | View SEC Doc Filr Page |
| 6-K | 2026-04-02 | 2026-04-02 | 6-K | 0001628280-26-022913 | View SEC Doc Filr Page |
| 20-F | 2026-04-01 | 2025-12-31 | 20-F | 0001598599-26-000005 | View SEC Doc Filr Page |